Clinical Trial

Rituximab+ Zanubrutinib for Patients With Hairy Cell Leukemia and Hairy Cell Variant

Name: Rituximab+ Zanubrutinib for Patients With Hairy Cell Leukemia and Hairy Cell Variant — clinical trial record (NCT07690761)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: Rituximab+ Zan

Enrolling by Invitation Phase 2

View on ClinicalTrials.gov →

Summary

investigators propose a phase II, open label-nonrandomized, single arm, multicenter study aiming to assess the safety and efficacy with the combination of Rituximab and Zanubrutinib in patients with HAIRY CELL LUKEMIA HCL, or HAIRY CELL LEUKEMIA VARIANT-HCLv.

Trial Details

NCT Number	NCT07690761
Lead Sponsor	Bnai Zion Medical Center Collaborators: Meir Medical Center, Hadassah Medical Organization
Conditions	Hairy Cell Leukemia, Hairy Cell Leukemia Variant
Enrollment	12 participants
Start Date	2026-06-01
Primary Completion	2028-12-31 (estimated)
Study Completion	2033-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-07-08